Home >> Research Areas

Malignant Glioblastomas

Upregulation of GLT-1 for the treatment of malignant glioma: Approximately 19,000 cases of malignant glioblastomas are reported annually in the United States.  Treatment options are limited and the majority of patients succumb to the disease within 6–12 months.  It has recently been reported that down regulation of GLT-1 in glioblastomas creates an imbalance in brain glutamate levels. This promotes excitotoxic cells death of healthy tissue, allowing tumor expansion in the restricted space of the cranial cavity.  Previous studies have demonstrated that induced expression of recombinant GLT-1 in glioma cells inhibits tumor cell growth in vitro and in vivo, validating GLT-1 up-regulation as a viable target for the treatment of malignant gliobastoma.   Our goal is the identification of small molecules that induce GLT-1up-regulation, which will reinstatement of Glu homeostasis in the brain and prevent tumor growth.    Ultimately, the identification of GLT-1 expression enhancers will provide significant positive impact on the health and well-being of glioblastoma patients.

Temple University
Moulder Center for Drug Discovery Research

Temple University School of Pharmacy
3307 N Broad Street
Philadelphia, PA 19140